- Home
- JAZZ vs PAA Comparison
JAZZ vs PAA Comparison
Compare JAZZ & PAA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JAZZ | PAA |
|---|---|---|
| Founded | 2003 | 1981 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Natural Gas Distribution |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.8B | 12.0B |
| IPO Year | 2007 | N/A |
Fundamental Metrics
Financial Performance| Metric | JAZZ | PAA |
|---|---|---|
| Price | $169.80 | $17.71 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 15 | 10 |
| Target Price | ★ $199.20 | $20.44 |
| AVG Volume (30 Days) | 1.1M | ★ 3.0M |
| Earning Date | 11-05-2025 | 02-06-2026 |
| Dividend Yield | N/A | ★ 8.66% |
| EPS Growth | N/A | ★ 8.03 |
| EPS | N/A | ★ 1.21 |
| Revenue | $4,157,832,999.00 | ★ $46,917,000,000.00 |
| Revenue This Year | $6.00 | N/A |
| Revenue Next Year | $6.84 | $3.43 |
| P/E Ratio | ★ N/A | $14.46 |
| Revenue Growth | ★ 4.14 | N/A |
| 52 Week Low | $95.49 | $15.58 |
| 52 Week High | $182.99 | $21.00 |
Technical Indicators
Market Signals| Indicator | JAZZ | PAA |
|---|---|---|
| Relative Strength Index (RSI) | 58.58 | 57.60 |
| Support Level | $164.39 | $17.53 |
| Resistance Level | $172.00 | $17.89 |
| Average True Range (ATR) | 4.28 | 0.27 |
| MACD | -1.26 | -0.02 |
| Stochastic Oscillator | 78.09 | 53.85 |
Price Performance
Historical ComparisonAbout JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
About PAA Plains All American Pipeline L.P.
Plains All American Pipeline LP through its subsidiaries, engages in the pipeline transportation, terminaling, storage, and gathering of crude oil and natural gas liquids (NGL) in the United States and Canada. The company operates through two segments, Crude Oil and NGL. The Crude Oil segment offers gathering and transporting crude oil through pipelines, gathering systems, trucks, and barges or railcars. The NGL segment is involved in natural gas processing and NGL fractionation, storage, transportation, and terminalling. It generates the majority of its revenue from the Crude Oil segment.